The INTERCEPT Blood System (pathogen-reduced i.e. psoralen-treated) provides a proactive, FDA-approved approach to reduce the risk of transfusion-transmitted infection (TTI) in platelets, including sepsis due to bacterial contamination.1
The INTERCEPT® Blood System for Platelets uses amotosalen (a psoralen) and UVA light to cross-link nucleic acids irreversibly, thereby inactivating a broad spectrum of viruses, bacteria, and parasites, as well as donor T-cells (Figure 1).1 After platelet processing by the blood collection establishment, residual amotosalen is negligible and the platelet product has normal functional and storage characteristics.1 The INTERCEPT Blood System has been shown to be effective at reducing the risk of transfusion transmission of known pathogens, such as cytomegalovirus (CMV),1,2 and emerging pathogens, such as Zika virus.3
Additionally, the INTERCEPT Blood System inactivates donor T-cells, is an FDA (Food and Drug Administration) approved alternative to gamma irradiation for the prevention of transfusion-associated graft-versus-host disease (TA-GVHD), and meets the AABB standard 188.8.131.52 for prevention of TA-GVHD in platelet components.4
Figure 1: Broad Spectrum of pathogens inactivated by INTERCEPT
Amotosalen, a synthetic psoralen, was selected for use in the INTERCEPT Blood System for pathogen reduction from a group of over 100 psoralens due, in part, to its enhanced nucleic acid binding when exposed to UV light, in comparison to other psoralens.5,6 By binding nucleic acids, INTERCEPT treatment blocks replication of viruses, bacteria, parasites and T-cells, rendering them inactive. Platelet function is not substantially impacted by this process1
Figure 2: Mechanism of action of the INTERCEPT Blood System
Figure 3: Illuminator INTERCEPT Blood System processing set
Toxicology studies have shown wide safety margins for amotosalen and it's photoproducts. Incubation with a compound adsorption device (CAD) further reduces levels. Once this is complete, the platelets are transferred to a final bag for distribution to the hospital and are transfusion ready.
The INTERCEPT Blood System provides robust inactivation, reducing risk due to:
- Bacteria frequently implicated in septic transfusion reactions
- Emerging pathogens, such as chikungunya, dengue, Zika viruses
- Established threats such as HIV, HBV, HCV
- T-cells implicated in TA-GVHD
1. INTERCEPT Blood System for Platelets [Package Insert]. Concord, CA: Cerus Corporation; July 17, 2018.
2. Corash, L., et al., Photochemical decontamination of platelet concentrates prevents transfusion induced cytomegalovirus infection. Blood, 1994. 84(Suppl 1): p. 530a.
3. Food and Drug Administration Center for Biologics Evaluation and Research, Revised Recommendations for Reducing the Risk of Zika Virus Transmission by Blood and Blood Components, Department of Health and Human Services, Editor. 2016, US FDA: Washington, DC.
4. AABB, Standards for Blood Banks and Transfusion Services 31th Edition. 2018, AABB: Bethesda, MD.
5. Lin L, Cook DN, Wiesehahn GP, et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 1997;37:423-35.
6. Ciaravino V, McCullough T, Dayan AD. Pharmacokinetic and toxicology assessment of INTERCEPT (S-59 and UVA treated) platelets. Hum Exp Toxicol 2001;20:533-50